Tema ETF Trust Tema Heart & Health ETF

HRTS

Market cap $56.3M

With the start of 2026, the annual focus on weight loss resolutions presents a timely opportunity for financial advisors to discuss the investment potential of GLP-1 agonists with their clients. This class of drugs has fundamentally altered the healthcare sector's growth projections.

NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), the New York-based provider of innovative exchange traded funds (ETFs), has surpassed $1 billion in assets under management (AUM) in just two years since launch, achieved with less than $5m of initial seed AUM. Tema also announces the hiring of Devan O'Dowd as Head of Distribution and Ceri Llewelyn as Director of Marketing. Three highlights to note: Institutional Adoption: Tema estimates that over 90% of current AUM originates from Registered Inves.

For many of us, a new year often means a new chance to start fresh in our battle with weight. Thanks to interesting ETF product development, especially in the past year, it could also mean a chance to consider the investment opportunity in weight loss as a theme.

2024 was an amazing year for investment performance, with the broad market S&P 500 TR Index up over 28%. There were also some serious ETF milestones achieved this year.

Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakthroughs and developments and explore a few ways to get actionable exposure to them with ETFs.

With the completion of a close presidential election, roughly half of us are likely disappointed regardless of the winner. To counter the post-election blues, I identified some “happy” ETF themes to consider for investment.

In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications.

Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.

When markets correct, it is a good time to revisit which equity market sectors are “defensive” themes. Certain products and services are nondiscretionary in nature that we cannot live without.

The weight loss revolution sparked by Novo Nordisk last year is attracting many investors towards the high risk biotech sector. An ETF like HRTS gives a lower risk exposure to the sector.